IVF denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for IVF are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies IVF as "Experimental or Investigational" — and Why These Denials Are Appealable

A BlueCross BlueShield denial labeling IVF — or a specific component of an IVF protocol — as "experimental, investigational, or unproven" is one of the more frustrating denial types, because IVF has been a recognized standard of care for infertility for decades. These denials typically arise not from IVF as a whole, but from a specific technique or add-on used as part of your cycle: for example, a particular genetic testing protocol, a specialized embryo culture or selection technique, a novel trigger or support protocol, or an emerging laboratory method. Occasionally, a blanket plan exclusion attempts to categorize IVF broadly, but this is increasingly rare.

BCBS affiliates vary by state and employer contract in how they define "experimental or investigational." Obtain your specific affiliate's current IVF and infertility medical policy before filing.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (self-funded) or state law (fully insured), you have the right to a full internal review. Request the specific Clinical Policy Bulletin, the technology assessment standard applied, and the criteria for removing the "experimental" classification.
• External review (ACA §2719): After exhausting internal appeals, you may request independent external review within approximately 4 months (180 days) of denial. Expedited review is available if delay would harm your health.

## The Concrete Appeal Process

1. Identify exactly what BCBS labeled experimental: The denial must specify which component or technique is at issue. If the denial is vague, request clarification in writing. 2. Obtain BCBS's technology assessment criteria: BCBS plans typically use a defined set of criteria to classify a technology as experimental. Request this framework so your appeal responds to the exact standard. 3. Gather professional society support: Have your reproductive endocrinologist document that the technique or protocol at issue is consistent with current ASRM Practice Committee guidance and represents accepted clinical practice, not investigation. 4. Submit a Level 1 internal appeal with the prescriber's letter and any relevant professional-society position statements. 5. Escalate to external review if upheld — external IROs are often receptive to experimental-therapy denials when professional society support is well-documented.

## Documentation to Gather

• Prescriber letter: A detailed letter from your reproductive endocrinologist explaining that the specific technique or component at issue is an accepted standard of clinical practice, citing the ASRM guideline or relevant specialty society position.
• Clinical necessity documentation: Chart notes establishing why the specific protocol — including any add-on technique — was chosen for your clinical situation, not as an experiment but as the appropriate clinical approach.
• Infertility diagnosis and prior treatment records: Supporting the overall medical necessity of IVF.
• BCBS technology assessment criteria: The specific framework BCBS used to classify the technique, so your appeal addresses each criterion.

## Criteria-Mapping Structure

For each criterion BCBS uses to classify a technology as experimental, write a direct response citing: (1) professional society guidance confirming the technique is accepted practice, (2) your prescriber's clinical rationale, and (3) any relevant peer-reviewed literature your prescriber can identify. You need not cite statistics or trial names — your prescriber's reference to the ASRM guideline position, paired with a chart-based clinical rationale, is often sufficient. External reviewers apply the most stringent scrutiny to experimental-therapy denials when the professional society consensus is well-established.